Pharming Group N.V.

PHAR

$1.27B

Small Cap

NASDAQBiotechnology🇺🇸North America404 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Jun 15, 2026

20w

Market Overview

Stock performance and market intelligence

Catalyst Timeline

2 upcoming, 0 past

🎯PDUFANext

✅Approved

FDA PDUFA Date leniolisib (priority)

4/15/2026

For Primary Immunodeficiency Diseases. NDA filing. Extracted from SEC filing: 6-K

Source

🎯PDUFA

FDA PDUFA Date leniolisib (priority)

6/15/2026

For rare primary immunodeficiency disease. NDA filing. Extracted from SEC filing: 6-K

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

No drugs found in this phase.

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

PHAR News

Pharming Group N.V.

PHAR

$1.27B

Small Cap

NASDAQBiotechnology🇺🇸North America404 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Jun 15, 2026

20w

Market Overview

Stock performance and market intelligence

Catalyst Timeline

2 upcoming, 0 past

🎯PDUFANext

✅Approved

FDA PDUFA Date leniolisib (priority)

4/15/2026

For Primary Immunodeficiency Diseases. NDA filing. Extracted from SEC filing: 6-K

Source

🎯PDUFA

FDA PDUFA Date leniolisib (priority)

6/15/2026

For rare primary immunodeficiency disease. NDA filing. Extracted from SEC filing: 6-K

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

No drugs found in this phase.

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

PHAR News